202 followers
538 followers
Congratulations to scientists involved in developing ABT-494 an oral 2nd gen, JAK-1 selective inhibitor for the treatment of RA, approved by the FDA today. https://t.co/lxG38cE4Zb https://t.co/h4rKQhyGwE
1,293 followers
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). https://t.co/8pUp0VoBER
1,384 followers
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). by Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ https://t.c